静脉注射免疫球蛋白对比标准治疗用于肾移植受者慢性活动性抗体介导排斥反应的随机对照试验
这项开放标签多中心随机对照试验(VIPAR)将30例活检证实的慢性活动性抗体介导排斥反应受者分配至每月1 g/kg共6剂IVIG组或不使用IVIG组。主要终点为慢性同种异体移植物损伤指数(CADI)斜率,不使用IVIG组CADI显著升高(+0.28/月,95%CI 0.14至0.41),而IVIG组未升高(-0.004/月,-0.13至0.12)。IVIG治疗与移植物组织学和eGFR稳定相关。
要点
- 不使用IVIG组CADI显著升高+0.28/月,IVIG组为-0.004/月。
- 不使用IVIG组eGFR下降更快(-1.1 ml/min/月) vs IVIG组(-0.4 ml/min/月)。
- 12个月内两组患者和移植物存活差异未显现。
核心结论
- IVIG治疗与肾移植受者慢性活动性AMR的移植物组织学和eGFR稳定相关。
研究设计与样本
- 开放标签多中心随机对照试验(VIPAR),纳入活检证实的慢性活动性AMR参与者,随机分配至IVIG组(1 g/kg/月,共6剂)或不使用IVIG组,每组15例。
主要发现
- 不使用IVIG组平均CADI显著升高(+0.28/月,95%CI 0.14至0.41),IVIG组未显著变化(-0.004/月,95%CI -0.13至0.12)。
- 两年内不使用IVIG组eGFR下降更迅速(-1.1 ml/min/月,95%CI -1.5至-0.7 ml/min/月) vs IVIG组(-0.4 ml/min/月,95%CI -0.8至0.03 ml/min/月)。
- 12个月内两组患者和移植物存活差异未显现。
- 与不使用IVIG相比,IVIG组移植物内59个基因(主要为B细胞相关)表达降低。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Chronic active antibody-mediated rejection (AMR) is the leading cause of death-censored kidney allograft loss, with no proven treatments. While intravenous immunoglobulin (IVIG) has been used in certain cases, its efficacy is unknown. METHODS: In this open-label multicenter randomized controlled trial (VIPAR), participants with biopsy-proven chronic active AMR, were assigned to six doses (1 g/kg/month) of IVIG or no-IVIG. The primary end point was the difference in slopes of the chronic allograft damage index (CADI) scores between groups, across four allograft biopsies (baseline, three, six and 12 months). Secondary outcomes, assessed at baseline, three, six and 12 months, included change in estimated glomerular filtration rate (eGFR), change in donor-specific anti-HLA antibodies (DSA), allograft and patient survival, and change in intra-graft mRNA expression. RESULTS: Fifteen participants were randomized to each arm. Their median age was 54.3 years, 22 were male and mean eGFR was 43.3 ml/min/1.73m2. Participants in the no-IVIg group experienced a significant increase in mean CADI (+0.28/month, 95% confidence interval 0.14 to 0.41), while the IVIG group did not (-0.004/month, -0.13 to 0.12). Over two years, eGFR significantly declined more rapidly in the no-IVIG group (-1.1 ml/min/month, -1.5 to -0.7 ml/min/month) than the IVIG group (-0.4 ml/min/month, -0.8 to 0.03 ml/min/month). Differences in patient and allograft survival were not evident by 12 months. Intra-graft expression of 59 genes (mostly B-cell related) reduced with IVIG relative to no-IVIG. CONCLUSIONS: IVIG therapy was associated with stabilization in allograft histology and eGFR in kidney transplant recipients with chronic active AMR. TRIAL REGISTRATION: Registered at https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=347495 with study number ACTRN12612000252819.
引用
- Mulley WR, Tharmaraj D, Polkinghorne KR, et al. A randomized controlled trial of intravenous immunoglobulin vs standard of care for the treatment of chronic active antibody-mediated rejection in kidney transplant recipients. Kidney Int. 2025. PMID: 40412552. doi:10.1016/j.kint.2025.04.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。